NCT06059469View on ClinicalTrials.gov

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

June 2, 2025

Study Completion Date

December 31, 2025

Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
DIAGNOSTIC_TEST

Ga-PSMA PET/CT

Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment

Trial Locations (1)

Unknown

RECRUITING

Institut Jules Bordet, Brussels

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER